User profiles for Hector Ortega

Hector Ortega

Nexstone Immunology, Inc.
Verified email at nsimmunology.com
Cited by 12852

[HTML][HTML] Mepolizumab treatment in patients with severe eosinophilic asthma

HG Ortega, MC Liu, ID Pavord… - New England journal …, 2014 - Mass Medical Soc
Background Some patients with severe asthma have frequent exacerbations associated with
persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled …

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

…, P Howarth, ER Bleecker, R Buhl, ON Keene, H Ortega… - The Lancet, 2012 - thelancet.com
Background Some patients with severe asthma have recurrent asthma exacerbations
associated with eosinophilic airway inflammation. Early studies suggest that inhibition of …

[HTML][HTML] Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma

…, ON Keene, SW Yancey, HG Ortega… - New England journal …, 2014 - Mass Medical Soc
Background Many patients with severe asthma require regular treatment with oral glucocorticoids
despite the use of high-dose inhaled therapy. However, the regular use of systemic …

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

HG Ortega, SW Yancey, B Mayer… - The Lancet …, 2016 - thelancet.com
Background Findings from previous studies showed that mepolizumab significantly reduces
the rate of exacerbations in patients with severe eosinophilic asthma. To assess the …

An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis

…, DA Smith, TL Perschy, CH Jurgensen, HG Ortega… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: The role of interleukin (IL)-5 in the pathogenesis of eosinophilic
esophagitis (EoE) has been established in animal models; anti–IL-5 therapy has been reported …

[HTML][HTML] Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study

…, MJ Gilson, RG Price, SW Yancey, HG Ortega - Clinical …, 2016 - Elsevier
Purpose Patients with severe eosinophilic asthma often experience recurrent asthma
exacerbations despite intensive inhaled corticosteroid therapy. In 2 previous double-blind studies (…

[HTML][HTML] Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

…, M Gilson, RG Price, SW Yancey, H Ortega - Journal of Allergy and …, 2019 - Elsevier
Background Mepolizumab has demonstrated favorable safety and efficacy profiles in
placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. …

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

…, AE Haig, SA Mallett, DN Templeton, HG Ortega… - Journal of allergy and …, 2013 - Elsevier
BACKGROUND: Hypereosinophilic syndromes (HESs) are chronic disorders that require
long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are …

Needs and opportunities for research in hypersensitivity pneumonitis

JN Fink, HG Ortega, HY Reynolds… - American journal of …, 2005 - atsjournals.org
Hypersensitivity pneumonitis (HP) develops after inhalation of many different environmental
antigens, causing variable clinical symptoms that often make diagnosis uncertain. The …

[HTML][HTML] Biomarkers for severe eosinophilic asthma

SW Yancey, ON Keene, FC Albers, H Ortega… - Journal of allergy and …, 2017 - Elsevier
The last decade has seen the approval of several new biologics for the treatment of severe
asthma-targeting specific endotypes and phenotypes. This review will examine how evidence …